| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Byakangelicol targets cyclooxygenase-2 (COX-2) (IC₅₀ for COX-2 activity inhibition: 15 μM; IC₅₀ for COX-2 induction inhibition: 25 μM) [1]
|
|---|---|
| ln Vitro |
Byakangelicol inhibited the catalytic activity of COX-2 in human pulmonary epithelial cells with an IC₅₀ value of 15 μM, as measured by prostaglandin E₂ (PGE₂) production assay [1]
It dose-dependently suppressed LPS-induced COX-2 induction in the same cell line, with an IC₅₀ value of 25 μM, reducing both COX-2 protein and mRNA expression levels [1] The compound did not significantly affect the activity of cyclooxygenase-1 (COX-1) at concentrations up to 100 μM, showing selectivity for COX-2 [1] LPS-induced PGE₂ production in human pulmonary epithelial cells was markedly reduced by Byakangelicol treatment, which was consistent with its inhibitory effect on COX-2 [1] |
| Enzyme Assay |
Human pulmonary epithelial cells were cultured to confluence, then lysed in ice-cold lysis buffer to prepare cell extracts containing COX enzymes [1]
For COX-2 activity assay: Cell extracts were mixed with reaction buffer containing arachidonic acid (substrate) and various concentrations of Byakangelicol (5, 10, 15, 20, 50 μM), then incubated at 37°C for 15 minutes [1] The reaction was terminated by adding acidified ethanol, and the amount of PGE₂ produced was quantified using a specific immunoassay to determine COX-2 activity and calculate IC₅₀ value [1] For COX-1 selectivity assay: The same experimental procedure was performed with COX-1-rich cell extracts, and PGE₂ production was measured to evaluate the effect of Byakangelicol on COX-1 activity [1] |
| Cell Assay |
Human pulmonary epithelial cells were maintained in DMEM medium supplemented with 10% fetal bovine serum and antibiotics, cultured at 37°C in a 5% CO₂ incubator [1]
For COX-2 induction inhibition assay: Cells were seeded in 6-well plates, allowed to adhere overnight, pretreated with Byakangelicol (10, 25, 50 μM) for 1 hour, then stimulated with LPS (1 μg/mL) for 24 hours [1] Western blot analysis: Cells were lysed, protein concentrations were determined, equal amounts of protein were separated by SDS-PAGE, transferred to PVDF membranes, incubated with primary antibody against COX-2 and β-actin (loading control), followed by secondary antibody, and protein bands were visualized using chemiluminescence detection [1] RT-PCR analysis: Total RNA was extracted from treated cells, reverse-transcribed into cDNA, PCR amplification was performed with specific primers for COX-2 and GAPDH (housekeeping gene), and relative mRNA expression levels were analyzed by gel electrophoresis and densitometry [1] PGE₂ production assay: Culture supernatants from LPS-stimulated cells were collected, and PGE₂ concentrations were measured using a competitive enzyme immunoassay kit [1] |
| References | |
| Additional Infomation |
Angelica dahurica belongs to the psoralen class of compounds.
It has been reported that angelica dahurica is found in St. John's wort, Angelica dahurica, and other organisms with relevant data. Angelica dahurica is a natural compound isolated from the root of Angelica dahurica[1]. Its anti-inflammatory effect is achieved through dual inhibition of COX-2: direct inhibition of the enzyme's catalytic activity and inhibition of LPS-induced COX-2 gene transcription and protein synthesis[1]. Angelica dahurica's selectivity for COX-2 compared to COX-1 suggests a potential therapeutic advantage by reducing gastrointestinal side effects associated with non-selective COX inhibitors[1]. |
| Molecular Formula |
C₁₇H₁₆O₆
|
|---|---|
| Molecular Weight |
316.31
|
| Exact Mass |
316.094
|
| CAS # |
26091-79-2
|
| PubChem CID |
3055167
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
503.4±50.0 °C at 760 mmHg
|
| Melting Point |
106℃
|
| Flash Point |
258.3±30.1 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.592
|
| LogP |
2.05
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
23
|
| Complexity |
515
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC1([C@H](O1)COC2=C3C(=C(C4=C2OC(=O)C=C4)OC)C=CO3)C
|
| InChi Key |
ORBITTMJKIGFNH-LLVKDONJSA-N
|
| InChi Code |
InChI=1S/C17H16O6/c1-17(2)11(23-17)8-21-16-14-10(6-7-20-14)13(19-3)9-4-5-12(18)22-15(9)16/h4-7,11H,8H2,1-3H3/t11-/m1/s1
|
| Chemical Name |
9-[[(2R)-3,3-dimethyloxiran-2-yl]methoxy]-4-methoxyfuro[3,2-g]chromen-7-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~316.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.90 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.90 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1615 mL | 15.8073 mL | 31.6146 mL | |
| 5 mM | 0.6323 mL | 3.1615 mL | 6.3229 mL | |
| 10 mM | 0.3161 mL | 1.5807 mL | 3.1615 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
